| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortison + polymyxin B 5 mg/10.000 enheder dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| polymyxin B-sulfat + trimethoprimsulfat 10.000 enheder/1 mg opløsning til oftalmisk anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Neo-tabs 500mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Mycifradin 125mg/5mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Neo-fradin 125mg/5mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| neomycinsulfat + polymyxin B-sulfat + prednisolonacetat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| gramicidin + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Polymyxin b sulfate + trimethoprim sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| colistinsulfat + hydrocortisonacetat + neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| bacitracinzink + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| hydrocortisonacetat + neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| dexamethason + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| cetylpyridiniumchlorid + ascorbinsyre |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat +neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Bacitracin zinc + polymyxin b sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat +neomycinsulfat 0,5 %/0,5 % øjen-/øredråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely benzocaine 10 milligram and cetylpyridinium chloride 1.4 milligram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| clobetasolpropionat + neomycinsulfat + nystatin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| cyklisk lipopeptid-antibiotikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing daptomycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Fluocinolone acetonide 250 microgram/g and neomycin sulfate 5 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Neomycin 0.5% ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| daptomycin 250 mg injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| daptomycin 500 mg injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing lidocaine and neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing neomycin and polymyxin B and pramocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing bacitracin and neomycin and polymyxin B and pramocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing neomycin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely betamethasone (as betamethasone sodium phosphate) 1 milligram/1 milliliter and neomycin sulfate 5 milligram/1 milliliter conventional release ear and eye and nose drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Betamethasone (as betamethasone valerate) 1 mg/g and neomycin sulfate 5 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Betamethasone+neomycin sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely chlorhexidine hydrochloride 1 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Chlorhexidine hydrochloride+neomycin sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| clobetasonbutyrat + neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Iodophore (substance) |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely cetylpyridinium chloride 1 milligram/1 gram and lidocaine hydrochloride 3.3 milligram/1 gram conventional release dental gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing chlorocresol and potassium hydroxyquinoline sulfate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| chlorcresol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing cetylpyridinium and lidocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing betamethasone and neomycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing precisely neomycin 3.5 milligram/1 milliliter and triamcinolone acetonide 1 milligram/1 milliliter conventional release ear drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing methylprednisolone and neomycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing neomycin and triamcinolone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing polymyxin B and trimethoprim (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing bacitracin and polymyxin B (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing cetylpyridinium and guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Product containing cetylpyridinium and menthol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Mercuric oxide |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| topikal carbol-fuchsin-opløsning |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Halquinol |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Undecoylium chloride iodine |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| Sodium meralein |
Is a |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| forgiftning med lokalt antiinfektiøst og antiinflammatorisk middel |
Causative agent |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
| forgiftning med antiinfektiøst middel til lokal anvendelse |
Causative agent |
False |
Antiinfektiøst middel til huden |
Inferred relationship |
Some |
|
FHIR